Live attenuated tetravalent dengue vaccine

Vaccine

Volumn 18, Issue SUPPL. 2, 2000, Pages 44-47

  Bhamarapravati, N ^a   Sutee, Y ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; LIVE VACCINE;

ADOLESCENT; ADULT; CHILD; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; DRUG EFFICACY; DRUG SAFETY; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; KIDNEY CELL; MAJOR CLINICAL STUDY; MYALGIA; PRIORITY JOURNAL; PRURITUS; SHORT SURVEY;

EID: 0034724248     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00040-2     Document Type: Article

References (15)

1. Eckels K.H., Scott R.M., Bancroft W.H., Brown J., Dubois D.R., Summers P.L., Russell P.K., Halstead S.B. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells: V. Human response to immunization with a candidate vaccine prepared in fetal rhesus lung cells. Am. J. Trop. Med. Hyg. 33:1984;684-689.
2. Sabin A.B., Schlesinger R.W. Production of immunity to dengue with virus modified by propagation in mice. Science. 101:1945;640-642.
3. Schlesinger R.W. Dengue virus. Virology Monograph No. 16. 1977;8-113 Springer, Vienna.
4. Angsubhakorn S., Moe J.B., Marchette N.J., Palumbo N.E., Yoksan S., Bhamarapravati N. Neurovirulence effects of dengue-2 viruses on the rhesus (Macaca mulatta) brain and spinal cord. Southeast Asian J. Trop. Med. Pub. Hlt. 18:(1):1987;52-55.
5. Angsubhakorn S., Moe J.B., Marchette N.J., Latendresse J.R., Palumbo N.E., Yoksan S., Bhamarapravati N. Neurovirulence detection of dengue virus using rhesus and cynomolgus monkeys. J. Virol. Meth. 18:1987;13-24.
6. Angsubhakorn S., Yoksan S., Bhamarapravati N., Moe J.B., Marchette N.J., Pradermwong A., Sahaphong S. Dengue-4 vaccine: neurovirulence, viraemia and immune responses in rhesus and cynomolgus monkeys. Trans. Roy. Soc. Trop. Med. Hyg. 82:1988;746-749.
7. Angsubhakorn S., Yoksan S., Pradermwong A., Nitatpattana N., Sahaphong S., Bhamarapravati N. Dengue-3 (16562) PGMK 33 Vaccine: neurovirulence, viremia and immune responses in Macaca fascicularis. Southeast Asian J. Trop. Med. Pub. Hlth. 25:(3):1994;554-559.
8. Yoksan S., Bhamarapravati N., Halstead S.B. Dengue virus vaccine development: study on biological markers of uncloned dengue 1-4 viruses serially passaged in primary cells. George T.D. Arbovirus Research in Australia, Proceedings Fourth Symposium 6-9 May. 1986;35-38.
9. Khin M.M., Jirakanjanakit N., Yoksan S., Bhamarapravati N. Infection, dissemination, transmission, and biological attributes of dengue-2 PDK 53 candidate vaccine virus after oral infection in Aedes aegypti. Am. J. Trop. Med. Hyg. 51:(6):1994;864-869.
10. Jirakanjanakit N., Khin M.M., Yoksan S., Bhamarapravati N. Dynamics of susceptibility and transmissibility of the live, attenuated, candidate vaccines dengue-1 PDK 13, dengue-3 PGMK30F3, and dengue-4 PDK 48 after oral infection in Aedes aegypti. Am. J. Trop. Med. Hyg. 61:(4):1999;672-676.
11. Gubler D.J., Kuno G. Dengue and dengue hemorrhagic fever. 1997;CAB International, UK.
12. Bhamarapravati N., Yoksan S., Chayaniyayothin T., Angsubphakorn S., Bunyaratvej A. Immunization with a live attenuated dengue-2 virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers. Bull. WHO. 65:(2):1987;189-195.
13. Bhamarapravati N., Yoksan S., Angsubphakorn S., Khin M.M., Darakul T. Clinical trials of live attenuated dengue vaccine current status. International Symposium on Current Situation of Dengue Virus Infection and its Control, 10-12 October, Nagasaki, Japan. 1993.
14. Vaughn D.W., Hoke C.H., Yoksan S., LaChance R., Innis B.L., Rice R.M., Bhamarapravati N. Testing of a dengue-2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers. Vaccine. 14:(4):1996;329-336.
15. Bhamarapravati N., Yoksan S. Study of bivalent dengue vaccine in volunteers. The Lancet. 13 May:1989;1077.